NCT03157414View on ClinicalTrials.gov

Empagliflozin in Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions
Diabetes MellitusRenal InsufficiencySafety Issues
Interventions
DRUG

Empagliflozin

Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose

OTHER

Placebo

Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose

Trial Locations (1)

0424

Oslo University Hospital Rikshospitalet, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT03157414 - Empagliflozin in Renal Transplant Recipients | Biotech Hunter | Biotech Hunter